Your browser doesn't support javascript.
loading
miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity.
Serr, Isabelle; Fürst, Rainer W; Ott, Verena B; Scherm, Martin G; Nikolaev, Alexei; Gökmen, Füsun; Kälin, Stefanie; Zillmer, Stephanie; Bunk, Melanie; Weigmann, Benno; Kunschke, Nicole; Loretz, Brigitta; Lehr, Claus-Michael; Kirchner, Benedikt; Haase, Bettina; Pfaffl, Michael; Waisman, Ari; Willis, Richard A; Ziegler, Anette-G; Daniel, Carolin.
Affiliation
  • Serr I; Institute for Diabetes Research, Independent Young Investigator Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany.
  • Fürst RW; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Klinikum rechts der Isar, Technische Universität München, 80939 Munich, Germany.
  • Ott VB; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Division of Metabolic Diseases, Technische Universität München, 85748 Munich, Germany.
  • Scherm MG; Institute for Diabetes Research, Independent Young Investigator Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany.
  • Nikolaev A; Institute for Molecular Medicine, Universitätsmedizin der Johannes Gutenberg-Universität, 55131 Mainz, Germany.
  • Gökmen F; Institute for Diabetes Research, Independent Young Investigator Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany.
  • Kälin S; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Division of Metabolic Diseases, Technische Universität München, 85748 Munich, Germany.
  • Zillmer S; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Klinikum rechts der Isar, Technische Universität München, 80939 Munich, Germany.
  • Bunk M; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Klinikum rechts der Isar, Technische Universität München, 80939 Munich, Germany.
  • Weigmann B; Department of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, 91052 Erlangen, Germany.
  • Kunschke N; Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, 66123 Saarbruecken, Germany.
  • Loretz B; Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, 66123 Saarbruecken, Germany.
  • Lehr CM; Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, 66123 Saarbruecken, Germany; Department of Pharmacy, Saarland University, 66123 Saarbruecken, Germany.
  • Kirchner B; Physiology Weihenstephan, Technische Universität München, 85354 Freising, Germany.
  • Haase B; Genomics Core Facility, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.
  • Pfaffl M; Physiology Weihenstephan, Technische Universität München, 85354 Freising, Germany.
  • Waisman A; Institute for Molecular Medicine, Universitätsmedizin der Johannes Gutenberg-Universität, 55131 Mainz, Germany.
  • Willis RA; Emory Vaccine Center, NIH Tetramer Core Facility, Atlanta, GA 30322.
  • Ziegler AG; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Klinikum rechts der Isar, Technische Universität München, 80939 Munich, Germany.
  • Daniel C; Institute for Diabetes Research, Independent Young Investigator Group Immune Tolerance in Type 1 Diabetes, Helmholtz Diabetes Center at Helmholtz Zentrum München, 80939 Munich, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Munich, Germany; carolin.daniel@helmholtz-muenchen.de.
Proc Natl Acad Sci U S A ; 113(43): E6659-E6668, 2016 10 25.
Article in En | MEDLINE | ID: mdl-27791035
Aberrant immune activation mediated by T effector cell populations is pivotal in the onset of autoimmunity in type 1 diabetes (T1D). T follicular helper (TFH) cells are essential in the induction of high-affinity antibodies, and their precursor memory compartment circulates in the blood. The role of TFH precursors in the onset of islet autoimmunity and signaling pathways regulating their differentiation is incompletely understood. Here, we provide direct evidence that during onset of islet autoimmunity, the insulin-specific target T-cell population is enriched with a C-X-C chemokine receptor type 5 (CXCR5)+CD4+ TFH precursor phenotype. During onset of islet autoimmunity, the frequency of TFH precursors was controlled by high expression of microRNA92a (miRNA92a). miRNA92a-mediated TFH precursor induction was regulated by phosphatase and tension homolog (PTEN) - phosphoinositol-3-kinase (PI3K) signaling involving PTEN and forkhead box protein O1 (Foxo1), supporting autoantibody generation and triggering the onset of islet autoimmunity. Moreover, we identify Krueppel-like factor 2 (KLF2) as a target of miRNA92a in regulating human TFH precursor induction. Importantly, a miRNA92a antagomir completely blocked induction of human TFH precursors in vitro. More importantly, in vivo application of a miRNA92a antagomir to nonobese diabetic (NOD) mice with ongoing islet autoimmunity resulted in a significant reduction of TFH precursors in peripheral blood and pancreatic lymph nodes. Moreover, miRNA92a antagomir application reduced immune infiltration and activation in pancreata of NOD mice as well as humanized NOD Scid IL2 receptor gamma chain knockout (NSG) human leucocyte antigen (HLA)-DQ8 transgenic animals. We therefore propose that miRNA92a and the PTEN-PI3K-KLF2 signaling network could function as targets for innovative precision medicines to reduce T1D islet autoimmunity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmunity / T-Lymphocytes, Helper-Inducer / MicroRNAs / Diabetes Mellitus, Type 1 / PTEN Phosphohydrolase / Kruppel-Like Transcription Factors Type of study: Prognostic_studies Limits: Adolescent / Animals / Child / Female / Humans / Male Language: En Journal: Proc Natl Acad Sci U S A Year: 2016 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmunity / T-Lymphocytes, Helper-Inducer / MicroRNAs / Diabetes Mellitus, Type 1 / PTEN Phosphohydrolase / Kruppel-Like Transcription Factors Type of study: Prognostic_studies Limits: Adolescent / Animals / Child / Female / Humans / Male Language: En Journal: Proc Natl Acad Sci U S A Year: 2016 Type: Article Affiliation country: Germany